Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger

Esperion Therapeutics (ESPR) stockholders approved the company’s merger agreement with Essence Parent and Essence MergerCo at a special meeting on July 8, 2026. The approval is a positive progression toward completing the deal, though no financial terms or timing were disclosed in the report.

Analysis

Esperion Therapeutics (ESPR) stockholders approved the company’s merger agreement with Essence Parent and Essence MergerCo at a special meeting on July 8, 2026. The approval is a positive progression toward completing the deal, though no financial terms or timing were disclosed in the report.